Combined Use of cyclinD1 and Ki67 for Prognosis of Luminal-Like Breast Cancer Patients
BackgroundKi67 is a biomarker of proliferation to be used in immunohistochemistry (IHC)-based surrogate assay to determine the necessity of cytotoxic therapy for Luminal-like breast cancer patients. cyclinD1 is another frequently used biomarker of proliferation. A retrospective study was performed h...
Guardado en:
Autores principales: | Junmei Hao, Wenfeng Zhang, Yan Lyu, Jiarui Zou, Yunyun Zhang, Jiahong Lyu, Jianbo Zhang, Shuishan Xie, Cuiping Zhang, Jiandi Zhang, Fangrong Tang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7d3287aa92df48ea9ea56251068666fa |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Diagnostic utility of Ki-67 and Cyclin D1 immunostaining in differentiation of psoriasis vs. other psoriasiform dermatitis
por: Engin Sezer, et al.
Publicado: (2015) -
The Correlate between Argyrophilic Nucleolar Organizer Region Stain and Ki-67 Immnochistochemistry in Diagnostic Breast Cancer
por: Hassan ALgarsh, et al.
Publicado: (2020) -
Expression of Endothelin-1 and Ki-67 in Normotensive and Severe Preeclamptic Placentas
por: Ekinci,Aysun, et al.
Publicado: (2018) -
Independent Clinical Validation of the Automated Ki67 Scoring Guideline from the International Ki67 in Breast Cancer Working Group
por: Ceren Boyaci, et al.
Publicado: (2021) -
HPV genotyping and p16/Ki-67 test significantly improve detection rate of high-grade cervical squamous intraepithelial lesion
por: Piotr Lewitowicz, et al.
Publicado: (2019)